brivaracetam vs cannabidiol
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of brivaracetam and cannabidiol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Briviact
Epidiolex
Brivaracetam is a medicine used to treat partial-onset seizures. It helps to reduce the number of seizures you have.
Epidiolex is a medicine that contains cannabidiol. It is used to treat seizures in people with certain conditions.
Brivaracetam is used to treat partial-onset seizures. These seizures start in one part of the brain. It can be used alone or with other seizure medicines for people 1 month and older.
Epidiolex is used to treat seizures linked to Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC). It is for patients who are at least 1 year old. These conditions can cause seizures that are hard to control.
Brivaracetam binds to a protein in the brain called SV2A. This helps to reduce the electrical activity in the brain that causes seizures. It helps to stabilize nerve cells.
Epidiolex contains cannabidiol, which is a substance that may affect how the brain works. It is thought to reduce seizures by acting on certain brain chemicals. The exact way it works is not fully understood.
- • Feeling sleepy or tired
- • Dizziness
- • Fatigue
- • Nausea or vomiting
- • Feeling sleepy
- • Decreased appetite
- • Diarrhea
- • Changes in liver blood tests
- • Feeling tired or weak
- Seizure 1,810
- Therapy Interrupted 280
- Overdose 233
- Fatigue 230
- Somnolence 216
- Seizure 5,791
- Hospitalisation 2,073
- Diarrhoea 1,695
- Somnolence 1,242
- Death 1,204
Brivaracetam can cause suicidal thoughts or actions. Watch for new or worsening depression, suicidal thoughts or behavior, or unusual changes in mood. Tell your doctor right away if you have any of these symptoms. Do not stop taking brivaracetam suddenly, as this may increase your risk of seizures.
Epidiolex can cause liver problems. Your doctor will check your liver before you start and during treatment. Tell your doctor right away if you feel very tired, have yellowing of the skin or eyes, dark urine, or loss of appetite. Epidiolex may also cause sleepiness or suicidal thoughts. Tell your doctor if you have any changes in mood or behavior.
Tell your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry for women who take brivaracetam during pregnancy. Contact the North American Antiepileptic Drug (NAAED) Pregnancy Registry at 1-888-233-2334.
Tell your doctor if you are pregnant or plan to become pregnant. Epidiolex may harm your unborn baby. There are pregnancy programs to monitor outcomes, so talk to your doctor about enrolling. It is not known if Epidiolex passes into breast milk, so talk to your doctor about the best way to feed your baby if you are taking this medicine.
How to Read This brivaracetam vs cannabidiol Comparison
brivaracetam is classified in the Anticonvulsant (SV2A Ligand) drug class, while cannabidiol sits within the Cannabinoid (Anticonvulsant) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, brivaracetam has 2,769 submissions while cannabidiol has 12,005. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for brivaracetam or cannabidiol.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.